KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Cash from Operations (2020 - 2025)

Ginkgo Bioworks Holdings (DNA) has disclosed Cash from Operations for 4 consecutive years, with 57831000.0 as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Cash from Operations rose 44.68% year-over-year to 57831000.0, compared with a TTM value of 295500000.0 through Dec 2023, down 17.17%, and an annual FY2025 reading of 171059000.0, up 46.47% over the prior year.
  • Cash from Operations was 57831000.0 for Q4 2023 at Ginkgo Bioworks Holdings, up from 73551000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 5235000.0 in Q3 2021 and bottomed at 165541000.0 in Q4 2021.
  • Average Cash from Operations over 4 years is 66219615.38, with a median of 59339000.0 recorded in 2020.
  • Peak annual rise in Cash from Operations hit 58.66% in 2022, while the deepest fall reached 441.76% in 2022.
  • Year by year, Cash from Operations stood at 59339000.0 in 2020, then plummeted by 178.98% to 165541000.0 in 2021, then skyrocketed by 36.85% to 104531000.0 in 2022, then surged by 44.68% to 57831000.0 in 2023.
  • Business Quant data shows Cash from Operations for DNA at 57831000.0 in Q4 2023, 73551000.0 in Q3 2023, and 73533000.0 in Q2 2023.